Global Musculoskeletal System Disorder Drug Market Analysis and Forecast 2025-2031

Summary

According to APO Research, The global Musculoskeletal System Disorder Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Musculoskeletal System Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Musculoskeletal System Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Musculoskeletal System Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Musculoskeletal System Disorder Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Musculoskeletal System Disorder Drug include Sanofi, Johnson & Johnson, Novartis, Eli Lilly, Pfizer, AbbVie, Torrent Pharmaceuticals, Nippon Shinyaku and Merck & Co, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Musculoskeletal System Disorder Drug, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Musculoskeletal System Disorder Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Musculoskeletal System Disorder Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Musculoskeletal System Disorder Drug revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Musculoskeletal System Disorder Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Musculoskeletal System Disorder Drug revenue, projected growth trends, production technology, application and end-user industry.

Musculoskeletal System Disorder Drug Segment by Company

Sanofi
Johnson & Johnson
Novartis
Eli Lilly
Pfizer
AbbVie
Torrent Pharmaceuticals
Nippon Shinyaku
Merck & Co
GSK
Eisai
Cadila Healthcare
Bayer
Astellas Pharma
Asahi Kasei
Amgen
Abbott
Musculoskeletal System Disorder Drug Segment by Type

Bone Disorder
Joint Disorder
Muscle Disorder
Other
Musculoskeletal System Disorder Drug Segment by Application

Hospital & Clinic
Retail Pharmacy
Other
Musculoskeletal System Disorder Drug Segment by Region

North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Musculoskeletal System Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Musculoskeletal System Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Musculoskeletal System Disorder Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Musculoskeletal System Disorder Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Musculoskeletal System Disorder Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Musculoskeletal System Disorder Drug revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Musculoskeletal System Disorder Drug Market by Type
1.2.1 Global Musculoskeletal System Disorder Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Bone Disorder
1.2.3 Joint Disorder
1.2.4 Muscle Disorder
1.2.5 Other
1.3 Musculoskeletal System Disorder Drug Market by Application
1.3.1 Global Musculoskeletal System Disorder Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital & Clinic
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Musculoskeletal System Disorder Drug Market Dynamics
2.1 Musculoskeletal System Disorder Drug Industry Trends
2.2 Musculoskeletal System Disorder Drug Industry Drivers
2.3 Musculoskeletal System Disorder Drug Industry Opportunities and Challenges
2.4 Musculoskeletal System Disorder Drug Industry Restraints
3 Global Growth Perspective
3.1 Global Musculoskeletal System Disorder Drug Market Perspective (2020-2031)
3.2 Global Musculoskeletal System Disorder Drug Growth Trends by Region
3.2.1 Global Musculoskeletal System Disorder Drug Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Musculoskeletal System Disorder Drug Market Size by Region (2020-2025)
3.2.3 Global Musculoskeletal System Disorder Drug Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Musculoskeletal System Disorder Drug Revenue by Players
4.1.1 Global Musculoskeletal System Disorder Drug Revenue by Players (2020-2025)
4.1.2 Global Musculoskeletal System Disorder Drug Revenue Market Share by Players (2020-2025)
4.1.3 Global Musculoskeletal System Disorder Drug Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Musculoskeletal System Disorder Drug Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Musculoskeletal System Disorder Drug Key Players Headquarters & Area Served
4.4 Global Musculoskeletal System Disorder Drug Players, Product Type & Application
4.5 Global Musculoskeletal System Disorder Drug Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Musculoskeletal System Disorder Drug Market CR5 and HHI
4.6.3 2024 Musculoskeletal System Disorder Drug Tier 1, Tier 2, and Tier 3
5 Musculoskeletal System Disorder Drug Market Size by Type
5.1 Global Musculoskeletal System Disorder Drug Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Musculoskeletal System Disorder Drug Revenue by Type (2020-2031)
5.3 Global Musculoskeletal System Disorder Drug Revenue Market Share by Type (2020-2031)
6 Musculoskeletal System Disorder Drug Market Size by Application
6.1 Global Musculoskeletal System Disorder Drug Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Musculoskeletal System Disorder Drug Revenue by Application (2020-2031)
6.3 Global Musculoskeletal System Disorder Drug Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Comapny Information
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.1.4 Sanofi Musculoskeletal System Disorder Drug Product Portfolio
7.1.5 Sanofi Recent Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Comapny Information
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.2.4 Johnson & Johnson Musculoskeletal System Disorder Drug Product Portfolio
7.2.5 Johnson & Johnson Recent Developments
7.3 Novartis
7.3.1 Novartis Comapny Information
7.3.2 Novartis Business Overview
7.3.3 Novartis Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.3.4 Novartis Musculoskeletal System Disorder Drug Product Portfolio
7.3.5 Novartis Recent Developments
7.4 Eli Lilly
7.4.1 Eli Lilly Comapny Information
7.4.2 Eli Lilly Business Overview
7.4.3 Eli Lilly Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.4.4 Eli Lilly Musculoskeletal System Disorder Drug Product Portfolio
7.4.5 Eli Lilly Recent Developments
7.5 Pfizer
7.5.1 Pfizer Comapny Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.5.4 Pfizer Musculoskeletal System Disorder Drug Product Portfolio
7.5.5 Pfizer Recent Developments
7.6 AbbVie
7.6.1 AbbVie Comapny Information
7.6.2 AbbVie Business Overview
7.6.3 AbbVie Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.6.4 AbbVie Musculoskeletal System Disorder Drug Product Portfolio
7.6.5 AbbVie Recent Developments
7.7 Torrent Pharmaceuticals
7.7.1 Torrent Pharmaceuticals Comapny Information
7.7.2 Torrent Pharmaceuticals Business Overview
7.7.3 Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.7.4 Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Product Portfolio
7.7.5 Torrent Pharmaceuticals Recent Developments
7.8 Nippon Shinyaku
7.8.1 Nippon Shinyaku Comapny Information
7.8.2 Nippon Shinyaku Business Overview
7.8.3 Nippon Shinyaku Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.8.4 Nippon Shinyaku Musculoskeletal System Disorder Drug Product Portfolio
7.8.5 Nippon Shinyaku Recent Developments
7.9 Merck & Co
7.9.1 Merck & Co Comapny Information
7.9.2 Merck & Co Business Overview
7.9.3 Merck & Co Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.9.4 Merck & Co Musculoskeletal System Disorder Drug Product Portfolio
7.9.5 Merck & Co Recent Developments
7.10 GSK
7.10.1 GSK Comapny Information
7.10.2 GSK Business Overview
7.10.3 GSK Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.10.4 GSK Musculoskeletal System Disorder Drug Product Portfolio
7.10.5 GSK Recent Developments
7.11 Eisai
7.11.1 Eisai Comapny Information
7.11.2 Eisai Business Overview
7.11.3 Eisai Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.11.4 Eisai Musculoskeletal System Disorder Drug Product Portfolio
7.11.5 Eisai Recent Developments
7.12 Cadila Healthcare
7.12.1 Cadila Healthcare Comapny Information
7.12.2 Cadila Healthcare Business Overview
7.12.3 Cadila Healthcare Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.12.4 Cadila Healthcare Musculoskeletal System Disorder Drug Product Portfolio
7.12.5 Cadila Healthcare Recent Developments
7.13 Bayer
7.13.1 Bayer Comapny Information
7.13.2 Bayer Business Overview
7.13.3 Bayer Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.13.4 Bayer Musculoskeletal System Disorder Drug Product Portfolio
7.13.5 Bayer Recent Developments
7.14 Astellas Pharma
7.14.1 Astellas Pharma Comapny Information
7.14.2 Astellas Pharma Business Overview
7.14.3 Astellas Pharma Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.14.4 Astellas Pharma Musculoskeletal System Disorder Drug Product Portfolio
7.14.5 Astellas Pharma Recent Developments
7.15 Asahi Kasei
7.15.1 Asahi Kasei Comapny Information
7.15.2 Asahi Kasei Business Overview
7.15.3 Asahi Kasei Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.15.4 Asahi Kasei Musculoskeletal System Disorder Drug Product Portfolio
7.15.5 Asahi Kasei Recent Developments
7.16 Amgen
7.16.1 Amgen Comapny Information
7.16.2 Amgen Business Overview
7.16.3 Amgen Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.16.4 Amgen Musculoskeletal System Disorder Drug Product Portfolio
7.16.5 Amgen Recent Developments
7.17 Abbott
7.17.1 Abbott Comapny Information
7.17.2 Abbott Business Overview
7.17.3 Abbott Musculoskeletal System Disorder Drug Revenue and Gross Margin (2020-2025)
7.17.4 Abbott Musculoskeletal System Disorder Drug Product Portfolio
7.17.5 Abbott Recent Developments
8 North America
8.1 North America Musculoskeletal System Disorder Drug Revenue (2020-2031)
8.2 North America Musculoskeletal System Disorder Drug Revenue by Type (2020-2031)
8.2.1 North America Musculoskeletal System Disorder Drug Revenue by Type (2020-2025)
8.2.2 North America Musculoskeletal System Disorder Drug Revenue by Type (2026-2031)
8.3 North America Musculoskeletal System Disorder Drug Revenue Share by Type (2020-2031)
8.4 North America Musculoskeletal System Disorder Drug Revenue by Application (2020-2031)
8.4.1 North America Musculoskeletal System Disorder Drug Revenue by Application (2020-2025)
8.4.2 North America Musculoskeletal System Disorder Drug Revenue by Application (2026-2031)
8.5 North America Musculoskeletal System Disorder Drug Revenue Share by Application (2020-2031)
8.6 North America Musculoskeletal System Disorder Drug Revenue by Country
8.6.1 North America Musculoskeletal System Disorder Drug Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Musculoskeletal System Disorder Drug Revenue by Country (2020-2025)
8.6.3 North America Musculoskeletal System Disorder Drug Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Musculoskeletal System Disorder Drug Revenue (2020-2031)
9.2 Europe Musculoskeletal System Disorder Drug Revenue by Type (2020-2031)
9.2.1 Europe Musculoskeletal System Disorder Drug Revenue by Type (2020-2025)
9.2.2 Europe Musculoskeletal System Disorder Drug Revenue by Type (2026-2031)
9.3 Europe Musculoskeletal System Disorder Drug Revenue Share by Type (2020-2031)
9.4 Europe Musculoskeletal System Disorder Drug Revenue by Application (2020-2031)
9.4.1 Europe Musculoskeletal System Disorder Drug Revenue by Application (2020-2025)
9.4.2 Europe Musculoskeletal System Disorder Drug Revenue by Application (2026-2031)
9.5 Europe Musculoskeletal System Disorder Drug Revenue Share by Application (2020-2031)
9.6 Europe Musculoskeletal System Disorder Drug Revenue by Country
9.6.1 Europe Musculoskeletal System Disorder Drug Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Musculoskeletal System Disorder Drug Revenue by Country (2020-2025)
9.6.3 Europe Musculoskeletal System Disorder Drug Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Musculoskeletal System Disorder Drug Revenue (2020-2031)
10.2 China Musculoskeletal System Disorder Drug Revenue by Type (2020-2031)
10.2.1 China Musculoskeletal System Disorder Drug Revenue by Type (2020-2025)
10.2.2 China Musculoskeletal System Disorder Drug Revenue by Type (2026-2031)
10.3 China Musculoskeletal System Disorder Drug Revenue Share by Type (2020-2031)
10.4 China Musculoskeletal System Disorder Drug Revenue by Application (2020-2031)
10.4.1 China Musculoskeletal System Disorder Drug Revenue by Application (2020-2025)
10.4.2 China Musculoskeletal System Disorder Drug Revenue by Application (2026-2031)
10.5 China Musculoskeletal System Disorder Drug Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Musculoskeletal System Disorder Drug Revenue (2020-2031)
11.2 Asia Musculoskeletal System Disorder Drug Revenue by Type (2020-2031)
11.2.1 Asia Musculoskeletal System Disorder Drug Revenue by Type (2020-2025)
11.2.2 Asia Musculoskeletal System Disorder Drug Revenue by Type (2026-2031)
11.3 Asia Musculoskeletal System Disorder Drug Revenue Share by Type (2020-2031)
11.4 Asia Musculoskeletal System Disorder Drug Revenue by Application (2020-2031)
11.4.1 Asia Musculoskeletal System Disorder Drug Revenue by Application (2020-2025)
11.4.2 Asia Musculoskeletal System Disorder Drug Revenue by Application (2026-2031)
11.5 Asia Musculoskeletal System Disorder Drug Revenue Share by Application (2020-2031)
11.6 Asia Musculoskeletal System Disorder Drug Revenue by Country
11.6.1 Asia Musculoskeletal System Disorder Drug Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Musculoskeletal System Disorder Drug Revenue by Country (2020-2025)
11.6.3 Asia Musculoskeletal System Disorder Drug Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Musculoskeletal System Disorder Drug Revenue (2020-2031)
12.2 SAMEA Musculoskeletal System Disorder Drug Revenue by Type (2020-2031)
12.2.1 SAMEA Musculoskeletal System Disorder Drug Revenue by Type (2020-2025)
12.2.2 SAMEA Musculoskeletal System Disorder Drug Revenue by Type (2026-2031)
12.3 SAMEA Musculoskeletal System Disorder Drug Revenue Share by Type (2020-2031)
12.4 SAMEA Musculoskeletal System Disorder Drug Revenue by Application (2020-2031)
12.4.1 SAMEA Musculoskeletal System Disorder Drug Revenue by Application (2020-2025)
12.4.2 SAMEA Musculoskeletal System Disorder Drug Revenue by Application (2026-2031)
12.5 SAMEA Musculoskeletal System Disorder Drug Revenue Share by Application (2020-2031)
12.6 SAMEA Musculoskeletal System Disorder Drug Revenue by Country
12.6.1 SAMEA Musculoskeletal System Disorder Drug Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Musculoskeletal System Disorder Drug Revenue by Country (2020-2025)
12.6.3 SAMEA Musculoskeletal System Disorder Drug Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings